Can early, tight glycaemic control prevent post-transplant diabetes mellitus?

Article Endocrinology & Metabolism

Early Post-Renal Transplant Hyperglycemia

Anira Iqbal et al.

Summary: Early post-renal transplant hyperglycemia (EPTH) is associated with significant complications and needs to be recognized and managed proactively. It increases the risk of acute graft failure, rehospitalizations, cardiovascular events, post-renal transplant diabetes, and infections.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)

Add to Collection

Review Urology & Nephrology

Management of post-transplant diabetes mellitus: an opportunity for novel therapeutics

Nuria Montero et al.

Summary: PTDM is a common issue after kidney transplantation, affecting 50% of high-risk recipients. KDIGO has updated guidelines for diabetes management in CKD, focusing on newer antidiabetic agents. Generating evidence is necessary to safely use these treatments and evaluate their potential cardiovascular and renal benefits in PTDM patients.

CLINICAL KIDNEY JOURNAL (2022)

Add to Collection

Review Pharmacology & Pharmacy

Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients

Sonya Anderson et al.

Summary: This systematic review discusses the efficacy, safety, and drug interactions of DPP-4 inhibitors, GLP-1 RAs, and SGLT2 inhibitors in kidney transplant recipients. It concludes that these newer antidiabetic agents can provide potential benefits in terms of cardiovascular, renal, and hypoglycemic outcomes, particularly in correcting PTDM-related defects, although there may be limitations such as urinary tract infections and reduced renal function with SGLT2 inhibitors in KTRs.

ANNALS OF PHARMACOTHERAPY (2021)

Add to Collection

Review Surgery

Management of post-transplant diabetes: immunosuppression, early prevention, and novel antidiabetics

Manfred Hecking et al.

Summary: PTDM is associated with risk factors such as obesity and immunosuppression, with SGLT2is and GLP1-RAs showing significant improvements in type 2 diabetes outcomes. However, the efficacy of these drugs may vary depending on kidney function. GLP1-RAs may be ideal for PTDM patients suffering from obesity.

TRANSPLANT INTERNATIONAL (2021)

Add to Collection

Article Surgery